the kinds of information and concepts being used by the committee. An extended report from the Committee on Biological Markers and its Subcommittee on Reproductive and Developmental Toxicology is in preparation and will be published separately by the National Academy Press and will contain the findings and conclusions of the committee.
Concepts and Definitions
Biological markers are indicators signaling events in biological systems or samples. It is useful to classify biological markers into three types, those of exposure, effect, and susceptibility, and to describe the events particular to each type. A biological marker of effect may be an indicator of an endogenous component of the biological system, a measure of the functional capacity of the system, or an altered state of the system that is recognized as impairment or disease. A biological marker of susceptibility is defined as an indicator that the health of the system is especially sensitive to the challenge of exposure to a xenobiotic compound (a compound originating outside the organism). A biological marker of exposure may be the identification of an exogenous substance within the system, the interactive product between a xenobiotic compound and endogenous components, or other event in the biological system related to the exposure. Of utmost importance is the correlation of biological markers of exposure with health impairment or potential health impairment.
It must be emphasized that there is a continuum between markers of exposure and markers of health status, with certain events being relatable to both types of markers. The terms biological monitoring and health monitoring are also in common use, and their distinguishing features are subject to debate (1) . In essence, biological markers can be used for both biological monitoring and health monitoring.
Once exposure has occurred, a continuum of biological events may be detected. These events may serve as markers of the initial exposure, internal dose, biologically effective dose (dose at the site of toxic action, dose at the receptor site, or dose to target macromolecules), altered structure/function with no subsequent pathology, or potential or actual health impairment (Fig. 1 
Markers of Effect
For present purposes, the effects on, or responses of, an organism to an exposure are considered in the context ofthe relationship of exposure to health impairment or the probability of health impairment. An Later in the course of the response to the xenobiotic compound, or after an internal dose reaches a sufficient duration or intensity, the affected tissue will exhibit altered function-a response that may be a subclinical manifestation of disease. Biological markers useful at this stage are likely to be related to the affected organ or system, for example, organ-specific markers as determined by biochemical analyses. When the biologically effective dose reaching the target tissue is sufficient to alter function irreversibly, overt disease may develop. Disease characteristics (e.g., acute neurotoxic, adverse cardiopulmonary, testicular, ovarian, fetal, or placental effects) occurring shortly after an exposure may be directly linked to the xenobiotic compound. However, it may be difficult to relate disease (e.g., ovarian or testicular failure) to an exposure distant in time unless the disease has characteristics or biological consequences (e.g., mesothelioma or chloracne) specific to a certain type of exposure. Most biological markers used to describe the disease state will be specific to the dis-eased organ or system and may have little relationship to the xenobiotic compound that initiated the disease process. For environmental health research, the most useful biological markers will be those that can be attributed to a specific environmental exposure.
Markers of Susceptibility
Some biological markers indicate individual or population differences that affect response to environmental agents independent of the exposure under study. An intrinsic genetic or other characteristic or a preexisting disease that results in an increase in the internal dose, the biologically effective dose, or the target tissue response can be markers of increased susceptibility (4). Such markers may include inborn differences in metabolism, variations in immunoglobulin levels, low organ reserve capacity, or other identifiable genetically determined or environmentally induced variations in absorption, metabolism, and response to environmental agents. Other factors that may affect individual susceptibilities include nutritional status of the organism, the role of the target site in overall body function, condition of the target tissue (present or prior disease), and compensation by homeostatic mechanisms during and after exposure (5) . The reserve capacity of an organ to recover from an insult at the time of exposure may also play an important role in determining the extent of an impairment.
Selection of Biological Markers
Ideally, a biological marker of exposure should vary consistently and quantitatively with the extent of exposure (especially at low doses) and should be specific for the environmental exposure of concern. Specific markers of exposure include the presence of a xenobiotic compound or its metabolites in body tissues or fluids and in excretory products. Blood and urine are the most commonly analyzed. For example, exposure to mercury, lead, or arsenic can be confirmed by the presence of the metal in urine; the determination ofp-nitrophenol in urine is used as an indicator of exposure to parathion, and the presence of chlorinated pesticides and polychlorinated biphenyls in adipose tissue is used as a marker of exposure to these lipophilic chemicals.
Other biological markers may reflect a particular change that is characteristic of exposure to specific xenobiotic compounds. Examples include the reduction of acetylcholinesterase activity in the plasma of persons exposed to organic phosphate insecticides (6) and the appearance of 8-aminolevulinic acid in the urine of those exposed to lead (7) . Nonspecific markers can also be useful, particularly if they can be related to environmental exposure. For example, serum a-fetoprotein (AFP) has been used in China as a biological marker for preneoplasia of the liver, which is common in that country. The production of AFP has been found to be proportional to the tumor load (8) . In addition, high levels of AFP in maternal serum suggest a fetal neural tube defect (9) , and low levels of AFP are associated with fetal karyotypic abnormalities (10, 11) . Accordingly, AFP is a nonspecific marker of health status. Its value for environmental health research would be in studies exploring the relationship of these disease entities to exposure.
A mechanistic approach to understanding the basic events resulting in an adverse health effect can be applied to the selection of an appropriate biological marker. This is best demonstrated in research on carcinogenesis. Many carcinogens have been shown to be mutagenic or otherwise damaging to DNA. Therefore, much research has been directed toward developing short-term assays for genetic toxicity, such as the Ames Salmonella mutation assay and tissue-culture assays for determining chromosomal aberrations or increased incidence of SCEs. These assays have been adapted to assess human exposure to potential carcinogens. For example, the Salmonella assay has been used to ascertain mutagenic activity in urine from persons exposed to mutagenic chemicals, e.g., by smoking cigarettes, by working with industrial chemicals, or as a result of treatment with cytostatic chemotherapeutic drugs (12) . The frequency of chromosomal aberrations and, more recently, lymphocyte SCEs has been used to assess human exposure to genotoxic agents, both physical (i.e., radiation) and chemical (13) . Techniques based on specific monoclonal and polyclonal antibodies, fluorescence spectrophotometry, thin-layer chromatography, and gas chromatography have been used to detect DNA adducts resulting from exposure to mutagens and carcinogens (14) .
Validation of Biological Markers
It is essential to validate the use of a biological change as an environmentally induced marker by establishing that a relationship exists between an exposure and the biological change of interest. One useful approach is to develop a matrix of information from experimental studies in animals and clinical studies in humans that enables one to make estimates for humans ( for chronic effects resulting from the long-term exposure of animals to the same pollutant could lead to the development of markers that are predictive of health effects in chronically exposed humans.
Quality Control
In addition to selection and validation, the development of adequate laboratory procedures for application of suitable tests to measure markers is fundamental to the assurance of accurate, objective, and verifiable findings. Most tests of quality assurance are statistical, based on an assumption of a Gaussian distribution of measurements (15,16), but some criteria for quality assurance transcend statistical criteria. They may involve considerations of sensitivity, instrument design, and methodology, as well as limitations on the applicability of tests in circumstances where the expected result may not be different from background levels (17) .
General issues of quality assurance and quality control have been addressed by the EPA (18) (19) (20) , the Food and Drug Administration (FDA) (21), the Organization for Economic Cooperation and Development (22) , and other regulatory organizations (23) (24) (25) (26) (27) . The FDA guidelines for good laboratory practice (GLP) (18) Since health risk is determined by a complex of exposures and effects in humans, in vivo studies in a variety of laboratory-animal models may be necessary to provide the background data required for the identification of appropriate biological markers. It will also be necessary to find markers that distinguish environmentally induced health changes from the background of disease due to other causes. Since the toxicity of some chemicals is mediated either by activation or by detoxification biotransformation reactions, and since these processes differ across species, it is important to establish that a test animal has a metabolic pathway similar to that of humans.
A frequent source of uncertainty in risk assessment is the shape of the dose-response curve at low levels of exposure (29,31). It is often impractical to conduct animal studies of effects at low doses, mainly because large numbers of animals are required to detect the relatively low incidence of effects that result from such exposures. Furthermore, environmentally induced health effects in humans are usually associated with high exposures and hence high risk. Sensitive molecular markers being developed will permit study of the relationships between low ambient levels of chemicals and the formation of a predictive molecular marker. This could lead to the demonstration of dose-response relationships pertinent to low-level human exposure.
None of these benefits or other potential benefits of biological markers will be possible, however, without extensive and continued research on the basic mechanisms by which chemicals interact with tissues and organs of humans and other organisms. The need to further our understanding of the biochemical interactions involved in the development of disease remains the first priority for environmental health research.
Ethical Issues
A number ofimportant ethical issues have been raised about the use of biological markers (32) (33) (34) (35) , especially about markers of susceptibility. Does society have an obligation to protect individuals beyond informing them of their risk? Can an employee be forced to leave his or her job once a susceptibility marker has been detected? There is concern that focusing on the detection of susceptible individuals could replace efforts to remove toxic chemicals from the workplace. Other ethical considerations arise from the degree to which susceptibility markers are predictive. For instance, it makes a difference whether the marker is totally predictive of an adverse response, reasonably highly predictive, or only minimally predictive.
Ethical issues also extend to the use of markers for making decisions about consumer products. For example, should an item of value or of convenience to the general public be withdrawn from commerce because a few individuals are susceptible to adverse effects from use of the product, or should susceptible individuals be responsible for avoiding contact with the product?
The history of our civilization contains many examples of ethical issues and questions raised by new developments in science and technology. As we move rapidly into an era of greater understanding of the interactions between genetic material and exogenous chemicals or other important biological interactions, we must anticipate and be prepared to address the ethical issues that will certainly arise.
Proceedings of the Symposium
The papers that follow reflect the individual perspectives of their authors on current understanding of biological markers in four areas: male reproductive toxicology, female reproductive toxicology, toxicological exposures during pregnancy, and neurodevelopmental toxicology. In general, toxicological studies in these fields have not yet reached the hazard identification stage. Much research in these areas is still needed to understand the mechanism of the relationship between exposure and health effect. Biological markers can be used to gain insight into these mechanisms, as well as to describe the empirical associations between exposures and outcomes.
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